Because Lp(a) is stable and measured once, its incorporation into diabetes risk assessments can identify high‐risk individuals for intensified lipid‐lowering or emerging Lp(a)‐targeted therapies, enhancing precision prevention. This evidence concerns the gene LPA and diabetes mellitus.